CLOs on the Move

Royalty Pharma

www.royaltypharma.com

 
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry`s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for ...
  • Number of Employees: 25-100
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
George Lloyd
Executive Vice President of Investments and Chief Legal Officer Profile
Arthur McGivern
Executive Vice President of Investments and General Counsel Profile
Yoon Suk Choo
VP, Investments and Deputy General Counsel Profile
Jason Mehar
Vice President of Investments and Deputy General Counsel Profile

Similar Companies

Entegrion

Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Carisma Therapeutics

Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.

Genitope Corporation

Genitope Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BlueWillow Biologics

NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.

NICO

NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.